Sfoglia per AUTORE
LARSON RA
Collezione AOU San Luigi di Orbassano

  

Items : 5

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM) in Journal of Clinical Oncology

2014
AOU San Luigi di Orbassano

Larson RA; Kim D-W; Jootar S; Pasquini R; Clark RE; Lobo C; Goldberg SL; Shibayama H; Hochhaus A; Saglio G; Kantarjian HM; Kemp C; Deng W; Menssen HD; Hughes TP;

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update in Journal of Clinical Oncology

2013
AOU San Luigi di Orbassano

Larson RA; Hochhaus A; Saglio G; Kim D-W; Jootar S; Le Coutre PD; Reiffers J; Pasquini R; Goldberg SL; Clark RE; Kemp CN; Fan X; Menssen HD; Hughes TP; Kantarjian HM;

Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd in Journal of Clinical Oncology

2013
AOU San Luigi di Orbassano

Saglio G; Hughes TP; Larson RA; Issaragrilsil S; Turkina AG; Steegmann JL; Lopez JL; Nakaseko C; Kalaycio ME; Huguet F; Kemp CN; Fan X; Menssen HD; Kantarjian HM; Hochhaus A;

Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u) in Journal of Clinical Oncology

2012
AOU San Luigi di Orbassano

Kantarjian H; Flinn IW; Goldberg S; Bunworasate U; Zanichelli MA; Nakamae H; Hughes TP; Hochhaus A; Saglio G; Woodman RC; Blakesley RE; Kemp CN; Kalaycio ME; Larson RA;

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. in The New England journal of medicine / N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.

2010
AOU San Luigi di Orbassano

Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;